Spleen volume variation in patients with locally advanced non-small cell lung cancer receiving platinum-based chemo-radiotherapy

Shu Wen Wen, Sarah J Everitt, Justin Bedo, Marine Chabrot, David L Ball, Benjamin J Solomon, Michael P MacManus, Rodney J Hicks, Andreas Moller, Antoine Leimgruber

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)


There is renewed interest in the immune regulatory role of the spleen in oncology. To date, very few studies have examined macroscopic variations of splenic volume in the setting of cancer, prior to or during therapy, especially in humans. Changes in splenic volume may be associated with changes in splenic function. The purpose of this study was to investigate variations in spleen volume in NSCLC patients during chemo-radiotherapy. Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). A baseline PET/CT scan was performed within 2 weeks prior to treatment and during Weeks 2 and 4 of chemo-radiotherapy. Spleen volume was measured by contouring all CT slices. Significant macroscopic changes in splenic volume occurred early after the commencement of treatment. A significant decrease in spleen volume was observed for 66 of Ca/P and 79 of Ci/E patients between baseline and Week 2. Spleen volume was decreased by 14.2 for Ca/P (p
Original languageEnglish
Article numbere0142608
Number of pages8
JournalPLoS ONE
Issue number11
Publication statusPublished - 24 Nov 2015

Cite this